Concert will present a corporate overview at the 2020 UBS Virtual Global Healthcare Conference on May 19, 2020 at 3:00 p.m. ET.
Concert will report its first quarter 2020 financial results and host a conference call and webcast on April 30, 2020.
Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Good morning and welcome to Concert Pharmaceuticals' first quarter 2020 investor update. Joining me this morning with prepared remarks are Roger Tung, our President and CEO; Jim Cassella, our Chief Development Officer; and Marc Becker, our CFO. As a reminder, today's discussion will include forward-looking statements about our future expectations, plans, and prospects.
It's nice to see the Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) share price up 20% in a week. But that doesn't help...
Concert (CNCE) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Concert's CEO will participate in a fireside chat in connection with the Jefferies Virtual Healthcare Conference on June 2 at 2:00 PM.
Concert (CNCE) delivered earnings and revenue surprises of 5.41% and -65.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Q1 2020 Concert Pharmaceuticals Inc Earnings Call
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Q4 2019 Concert Pharmaceuticals Inc Earnings Call
Concert announced the details of its pivotal Phase 3 trials of CTP-543 in patients with moderate-to-severe alopecia areata.
Concert will host a conference call and webcast April 30, 2020, at 8:30 a.m. ET to provide an update on the Company and discuss first quarter results.
Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Anyone researching Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) might want to consider the historical volatility of the...